Clinical Trial Update: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial update for mapracorat ophthalmic suspension 3% aimed at treating ocular inflammation and pain after cataract surgery; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Ocular Inflammation

Drugs mentioned

• Mapracorat Ophthalmic Suspension 3% (mapracorat)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Cataract, Inflammation | Phase 3 | Status: COMPLETED | Results posted: 2020-09-03